IL6 and coronary artery disorder: In addition, in a sub-analysis of the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial, plasma IL-6 levels in patients with stable CAD were associated with several health outcomes, including cardiovascular and all-cause mortality, myocardial infarction and heart failure [116].